The phase 3 FLAURA trial assessed the efficacy and safety of osimertinib in patients with previously untreated EGFR mutation–positive advanced NSCLC compared with standard EGFR-TKIs, gefitinib or erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.